On September 2009, Molecular Insights Pharmaceuticals (MIP) and BioMedica Life Sciences S.A. reached
to an agreement that provides BioMedica Life Sciences s.a an exclusive sub-license to OnaltaTM (90Y-DOTATOC)
trademark in Europe, the Middle East, North Africa, Russia and Turkey. Under this agreement,
BioMedica Life Sciences S.A. is expected to perform Clinical Studies and market, distribute
and commercialize OnaltaTM (90Y-DOTATOC) in the specified territories and secure all
regulatory approvals.
|
|
|
|
Biomedica Life Sciences S.A. is a privately held, vertically integrated Specialty Pharmaceutical Company,
headquartered in Greece (Athens), focused on the emerging field of Nuclear Medicine and more specifically
in the Molecular Imaging and Targeted Therapies. The Company since its establishment in 1987 is dynamically
active in the Health Sector and has established a leading position in covering the market needs of the health
industry in diagnostic and therapeutic products, specific medical devices and services. Biomedica Life
Sciences S.A. has launched and marketed a unique portfolio of innovative radiopharmaceutical products in Greece.
The Company’s core activity, utilizing the expertise that has been developed through the past years, spans over the following fields:
 |
Development and commercialization of innovative radiopharmaceutical products and services through internal R&D efforts
|
|
Sourcing late stage radiopharmaceutical diagnostics and therapies for development and commercialization in Europe, Turkey and the Middle East
|
|
Investing in research partnerships with academic institutions and research centers
|
|
|
|
|
|
